Literature DB >> 19088301

Nicotinic receptor activation increases [3H]dopamine uptake and cell surface expression of dopamine transporters in rat prefrontal cortex.

Jun Zhu1, Subbu Apparsundaram, Linda P Dwoskin.   

Abstract

Previous research shows that nicotine increases dopamine (DA) clearance in rat prefrontal cortex (PFC) and striatum via a nicotinic receptor (nAChR)-mediated mechanism. The present study investigated whether activation of nAChRs regulates DA transporter (DAT) function through a trafficking-dependent mechanism. After nicotine administration (0, 0.3, and 0.8 mg/kg s.c., 15-1440 min after injection), DAT function and trafficking in synaptosomes of PFC and striatum were determined. nAChR mediation of the effect of nicotine on DAT function and trafficking in PFC was determined by pretreatment with mecamylamine, dihydro-beta-erythroidine, or methyllycaconitine. Nicotine (0.8 mg/kg, 15 and 30 min after injection) increased the maximal velocity (V(max)) of [3H]DA uptake in PFC with no change in K(m), compared with control. Biotinylation and Western blot assays showed that nicotine (0.8 mg/kg; 30 min) increased DAT cell surface expression in PFC. In contrast, a lower dose of nicotine (0.3 mg/kg; 30 min) did not alter DAT function and trafficking in PFC. Pretreatment with mecamylamine, dihydro-beta-erythroidine, or methyllycaconitine (1.5, 8.0, and 10.0 mg/kg s.c., respectively) completely blocked the nicotine-induced increase in V(max) in PFC. In addition, mecamylamine completely blocked the nicotine-induced increase in DAT cell surface expression in PFC. Nicotine did not increase DAT function and cell surface expression in striatum, indicating that nicotine modulates DAT function in a brain region-specific manner. Thus, results from the present study suggest that the nicotine-induced increases in DAT function and cell surface expression in PFC may mediate some of the behavioral effects of nicotine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19088301      PMCID: PMC2682260          DOI: 10.1124/jpet.108.147025

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

Review 1.  The dopamine transporter proteome.

Authors:  Gonzalo E Torres
Journal:  J Neurochem       Date:  2006-04       Impact factor: 5.372

2.  Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine release.

Authors:  Ying-Jun Cao; Carol S Surowy; Pamela S Puttfarcken
Journal:  Neuropharmacology       Date:  2005-01       Impact factor: 5.250

3.  Blockade of nicotine self-administration with nicotinic antagonists in rats.

Authors:  S S Watkins; M P Epping-Jordan; G F Koob; A Markou
Journal:  Pharmacol Biochem Behav       Date:  1999-04       Impact factor: 3.533

4.  Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake.

Authors:  W A Cass; G A Gerhardt
Journal:  Neurosci Lett       Date:  1994-08-01       Impact factor: 3.046

5.  In vivo dopamine clearance rate in rat striatum: regulation by extracellular dopamine concentration and dopamine transporter inhibitors.

Authors:  N R Zahniser; G A Larson; G A Gerhardt
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

6.  Environmental enrichment decreases cell surface expression of the dopamine transporter in rat medial prefrontal cortex.

Authors:  Jun Zhu; Subbu Apparsundaram; Michael T Bardo; Linda P Dwoskin
Journal:  J Neurochem       Date:  2005-06       Impact factor: 5.372

7.  Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism.

Authors:  Tatiana Sorkina; Brian R Hoover; Nancy R Zahniser; Alexander Sorkin
Journal:  Traffic       Date:  2005-02       Impact factor: 6.215

8.  Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes.

Authors:  L E Chavez-Noriega; J H Crona; M S Washburn; A Urrutia; K J Elliott; E C Johnson
Journal:  J Pharmacol Exp Ther       Date:  1997-01       Impact factor: 4.030

9.  Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum.

Authors:  S D Dickinson; J Sabeti; G A Larson; K Giardina; M Rubinstein; M A Kelly; D K Grandy; M J Low; G A Gerhardt; N R Zahniser
Journal:  J Neurochem       Date:  1999-01       Impact factor: 5.372

10.  Nicotine effects on dopamine clearance in rat nucleus accumbens.

Authors:  C Hart; C Ksir
Journal:  J Neurochem       Date:  1996-01       Impact factor: 5.372

View more
  12 in total

1.  Upregulation of norepinephrine transporter function by prolonged exposure to nicotine in cultured bovine adrenal medullary cells.

Authors:  Hideaki Itoh; Yumiko Toyohira; Susumu Ueno; Satoru Saeki; Han Zhang; Yumi Furuno; Kojiro Takahashi; Masato Tsutsui; Kenji Hachisuka; Nobuyuki Yanagihara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-07-31       Impact factor: 3.000

Review 2.  Pharmacogenetics of nicotine addiction: role of dopamine.

Authors:  Aryeh I Herman; Elise E DeVito; Kevin P Jensen; Mehmet Sofuoglu
Journal:  Pharmacogenomics       Date:  2014-02       Impact factor: 2.533

3.  Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function.

Authors:  Roxann C Harvey; Sucharita Sen; Agripina Deaciuc; Linda P Dwoskin; Kathleen M Kantak
Journal:  Neuropsychopharmacology       Date:  2010-12-08       Impact factor: 7.853

4.  Effect of environmental enrichment on methylphenidate-induced locomotion and dopamine transporter dynamics.

Authors:  Thomas E Wooters; Michael T Bardo; Linda P Dwoskin; Narasimha M Midde; Adrian M Gomez; Charles F Mactutus; Rosemarie M Booze; Jun Zhu
Journal:  Behav Brain Res       Date:  2011-01-08       Impact factor: 3.332

5.  Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner.

Authors:  Hugo A Tejeda; Luis A Natividad; James E Orfila; Oscar V Torres; Laura E O'Dell
Journal:  Psychopharmacology (Berl)       Date:  2012-06-04       Impact factor: 4.530

6.  [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein.

Authors:  Matthew Strauss; Bernadette O'Donovan; Yizhi Ma; Ziyu Xiao; Steven Lin; Michael T Bardo; Pavel I Ortinski; Jay P McLaughlin; Jun Zhu
Journal:  J Pharmacol Exp Ther       Date:  2020-05-27       Impact factor: 4.030

7.  Gene expression profiling of midbrain dopamine neurons upon gestational nicotine exposure.

Authors:  Pınar Kanlikilicer; Die Zhang; Andrei Dragomir; Yasemin M Akay; Metin Akay
Journal:  Med Biol Eng Comput       Date:  2016-06-02       Impact factor: 2.602

8.  HIV-1 transgenic rats display an increase in [(3)H]dopamine uptake in the prefrontal cortex and striatum.

Authors:  Jun Zhu; Yaxia Yuan; Narasimha M Midde; Adrian M Gomez; Wei-Lun Sun; Pamela M Quizon; Chang-Guo Zhan
Journal:  J Neurovirol       Date:  2015-10-26       Impact factor: 2.643

9.  HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes.

Authors:  Narasimha M Midde; Adrian M Gomez; Jun Zhu
Journal:  J Neuroimmune Pharmacol       Date:  2012-05-05       Impact factor: 4.147

10.  Allosteric modulatory effects of SRI-20041 and SRI-30827 on cocaine and HIV-1 Tat protein binding to human dopamine transporter.

Authors:  Wei-Lun Sun; Pamela M Quizon; Yaxia Yuan; Wei Zhang; Subramaniam Ananthan; Chang-Guo Zhan; Jun Zhu
Journal:  Sci Rep       Date:  2017-06-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.